These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 36210877)

  • 1. Immunogenicity of COVID-19 mRNA vaccines in hemodialysis patients: Systematic review and meta-analysis.
    Falahi S; Sayyadi H; Kenarkoohi A
    Health Sci Rep; 2022 Nov; 5(6):e874. PubMed ID: 36210877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
    Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
    JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seroconversion following the first, second, and third dose of SARS-CoV-2 vaccines in immunocompromised population: a systematic review and meta-analysis.
    Mehrabi Nejad MM; Shobeiri P; Dehghanbanadaki H; Tabary M; Aryannejad A; Haji Ghadery A; Shabani M; Moosaie F; SeyedAlinaghi S; Rezaei N
    Virol J; 2022 Aug; 19(1):132. PubMed ID: 35941646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.
    Noori M; Azizi S; Abbasi Varaki F; Nejadghaderi SA; Bashash D
    Int Immunopharmacol; 2022 Sep; 110():109046. PubMed ID: 35843148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis.
    Lee ARYB; Wong SY; Chai LYA; Lee SC; Lee MX; Muthiah MD; Tay SH; Teo CB; Tan BKJ; Chan YH; Sundar R; Soon YY
    BMJ; 2022 Mar; 376():e068632. PubMed ID: 35236664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis.
    Verleye A; Wijtvliet V; Abrams S; Hellemans R; Bougrea R; Massart A; Pipeleers L; Wissing KM; Ariën KK; De Winter BY; Van Damme P; Abramowicz D; Ledeganck KJ
    Nephrol Dial Transplant; 2022 Jul; 37(8):1566-1575. PubMed ID: 35544087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
    Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
    Front Immunol; 2021; 12():704773. PubMed ID: 34220867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in patients with chronic lymphocytic leukemia: a prospective study.
    Diamantopoulos PT; Stafylidis C; Vlachopoulou D; Kontandreopoulou CN; Giannakopoulou N; Vardaka M; Mpouhla A; Mastrogianni E; Variami E; Galanopoulos A; Pappa V; Psichogiou M; Hatzakis A; Viniou NA
    Ther Adv Hematol; 2022; 13():20406207221090150. PubMed ID: 35646300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: a systematic review and meta-analysis.
    Yin J; Chen Y; Li Y; Wang C; Zhang X
    Int J Infect Dis; 2022 Nov; 124():212-223. PubMed ID: 36241168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Qualitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV.
    Tuan JJ; Zapata H; Critch-Gilfillan T; Ryall L; Turcotte B; Mutic S; Andrews L; Roh ME; Friedland G; Barakat L; Ogbuagu O
    HIV Med; 2022 Feb; 23(2):178-185. PubMed ID: 34632695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of SARS-CoV-2 vaccine in hemodialysis patients: A systematic review and meta-analysis.
    Peiyao R; Mengjie Y; Xiaogang S; Wenfang H; Danna Z; Yuqun Z; Juan J; Qiang H
    Front Public Health; 2022; 10():951096. PubMed ID: 36211647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody responses to the SARS-CoV-2 vaccines in hemodialysis patients: Is inactivated vaccine effective?
    Murt A; Altiparmak MR; Yadigar S; Yalin SF; Ozbey D; Yildiz Z; Kocazeybek B; Pekpak M; Ataman MR
    Ther Apher Dial; 2022 Aug; 26(4):769-774. PubMed ID: 34741418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Meta-Analysis on the Safety and Immunogenicity of Covid-19 Vaccines.
    Ashmawy R; Hamdy NA; Elhadi YAM; Alqutub ST; Esmail OF; Abdou MSM; Reyad OA; El-Ganainy SO; Gad BK; Nour El-Deen AE; Kamal A; ElSaieh H; Elrewiny E; Shaaban R; Ghazy RM
    J Prim Care Community Health; 2022; 13():21501319221089255. PubMed ID: 35400233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
    Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
    Front Immunol; 2021; 12():690698. PubMed ID: 34276681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors predictive of anti-spike antibody titers after COVID-19 vaccination in hemodialysis patients.
    Aoun M; Kahwaji RM; Sleilaty G; Boueri C; Hawi J; Khalil CB; Hage V
    Adv Clin Exp Med; 2022 Aug; 31(8):855-861. PubMed ID: 35438849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis.
    Goupil R; Benlarbi M; Beaubien-Souligny W; Nadeau-Fredette AC; Chatterjee D; Goyette G; Gunaratnam L; Lamarche C; Tom A; Finzi A; Suri RS;
    CMAJ; 2021 May; 193(22):E793-E800. PubMed ID: 33980499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis.
    Sharif N; Alzahrani KJ; Ahmed SN; Dey SK
    Front Immunol; 2021; 12():714170. PubMed ID: 34707602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of COVID-19 Vaccination in Patients With End-Stage Renal Disease Undergoing Maintenance Hemodialysis: The Efficacy of a Mix-and-Match Strategy.
    Park JS; Minn D; Hong S; Jeong S; Kim S; Lee CH; Kim B
    J Korean Med Sci; 2022 Jun; 37(23):e180. PubMed ID: 35698835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral Response after Three Doses of mRNA-1273 or BNT162b2 SARS-CoV-2 Vaccines in Hemodialysis Patients.
    Broseta JJ; Rodríguez-Espinosa D; Cuadrado E; Rodríguez N; Bedini JL; Maduell F
    Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.